188 / 1481
PET: Weaknesses
•
Needs matching with morphological techniques
•
PET/CT or PET/MRI hybrid scanners
•
Possible matching errors in moving structures
•
Size of hot areas dependent on windowing
•
Does not show real tumour extension
•
FDG-PET not necessarily tumour-specific
•
Uptake in inflammatory conditions
•
Some tumours need specific tracers
•
68
Ga-DOTATOC for neuroendocrine tumours
•
PSMA ligand for prostate cancer